AB-Biotics to Spotlight Probiotics for Women’s Health
04.24.24
The company has tailored blends of probiotic strains to target menopause relief, urinary tract health, and restoration of vaginal microbiota.
Booth B100
AB-BIOTICS, a Kaneka company, will exhibit at this year’s Vitafoods Europe to showcase scientific findings on its latest probiotic solutions for women’s health and sports nutrition.
Women’s Health
Marta Pérez, PhD, the company’s R&D manager, will be presenting at the Biotics Theater on May 15 on the role probiotics can play in managing symptoms of menopause and how AB-BIOTICS translates this into its products.
The company recently launched a blend of L. plantarum KABP 051, L. brevis KABP 052, and P. acidilactici KABP 021, to support managing all stages of menopause via a mechanism that regulates estrogen levels in the gut. In the session “Understanding Menopause,” Pérez will discuss the clinical study investigating the mechanism of action and capacity of the blend.
The company will also discuss other clinical research on products in its Gyntima portfolio, such as Gyntima Cyscare, which is formulated to protect the urinary tract from infections, and Gyntima Balance, a formulation to support restoration of the vaginal microbiota.
The company will also feature Gyntima Re-Balance, a medical device targeting vaginal infections and bacterial vaginosis.
Sports Nutrition
The company will showcase preliminary results for a clinical trial on a product branded as i3.1, which contains the strains L. plantarum KABP 022, L. plantarum KABP 023 and P. acidilactici KABP 021, which was linked to reductions in digestive complaints linked to intense physical exercise. The new, unpublished study also suggested that it could facilitate the recovery of gastrointestinal function post-exercise.
Additional Health Targets
Experts will also discuss the findings of a recently-published study focused on probiotics for cardiovascular health. L. plantarum strains KABP 011, KABP 012 and KABP 013, marketed as AB-LIFE, have been shown to lower cholesterol by impacting low-density lipoprotein (LDL) particle size and apoliproteins, all of which are relevant biomarkers in atherosclerosis.
Further, visitors can learn about AB-Kolicare, specifically developed to target colic and gut maturation in infants; AB21, a formulation evidenced to reduce the risk of viral infection; and AB-Digest, a formula to target dysbiosis associated with antibiotic treatments.
AB-BIOTICS, a Kaneka company, will exhibit at this year’s Vitafoods Europe to showcase scientific findings on its latest probiotic solutions for women’s health and sports nutrition.
Women’s Health
Marta Pérez, PhD, the company’s R&D manager, will be presenting at the Biotics Theater on May 15 on the role probiotics can play in managing symptoms of menopause and how AB-BIOTICS translates this into its products.
The company recently launched a blend of L. plantarum KABP 051, L. brevis KABP 052, and P. acidilactici KABP 021, to support managing all stages of menopause via a mechanism that regulates estrogen levels in the gut. In the session “Understanding Menopause,” Pérez will discuss the clinical study investigating the mechanism of action and capacity of the blend.
The company will also discuss other clinical research on products in its Gyntima portfolio, such as Gyntima Cyscare, which is formulated to protect the urinary tract from infections, and Gyntima Balance, a formulation to support restoration of the vaginal microbiota.
The company will also feature Gyntima Re-Balance, a medical device targeting vaginal infections and bacterial vaginosis.
Sports Nutrition
The company will showcase preliminary results for a clinical trial on a product branded as i3.1, which contains the strains L. plantarum KABP 022, L. plantarum KABP 023 and P. acidilactici KABP 021, which was linked to reductions in digestive complaints linked to intense physical exercise. The new, unpublished study also suggested that it could facilitate the recovery of gastrointestinal function post-exercise.
Additional Health Targets
Experts will also discuss the findings of a recently-published study focused on probiotics for cardiovascular health. L. plantarum strains KABP 011, KABP 012 and KABP 013, marketed as AB-LIFE, have been shown to lower cholesterol by impacting low-density lipoprotein (LDL) particle size and apoliproteins, all of which are relevant biomarkers in atherosclerosis.
Further, visitors can learn about AB-Kolicare, specifically developed to target colic and gut maturation in infants; AB21, a formulation evidenced to reduce the risk of viral infection; and AB-Digest, a formula to target dysbiosis associated with antibiotic treatments.
